By Dr Louise Emmett

Journal articles

Emmett L; Pattison DA; Roberts MJ, 2022, 'All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others', European Urology Oncology, 5, pp. 283 - 284, http://dx.doi.org/10.1016/j.euo.2022.04.002

Lee ST; Emmett LM; Pattison DA; Hofman MS; Bailey DL; Latter MJ; Francis RJ; Scott AM, 2022, 'The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective', Journal of Nuclear Medicine, 63, pp. 819 - 822, http://dx.doi.org/10.2967/JNUMED.122.263996

Dieng M; Lord SJ; Turner RM; Nieweg OE; Menzies AM; Saw RPM; Einstein AJ; Emmett L; Thompson JF; Lo SN; Morton RL, 2022, 'The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma', Annals of Surgical Oncology, 29, pp. 2871 - 2881, http://dx.doi.org/10.1245/s10434-021-11231-3

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Roberts MJ; Emmett L, 2022, 'EDITORIAL COMMENT', Journal of Urology, 207, pp. 348 - 349, http://dx.doi.org/10.1097/JU.0000000000002254.01

Liu W; Fakir H; Randhawa G; Alfano R; Corkum M; Kassam Z; Rachinsky I; Chung HT; Chung P; Loblaw A; Morton G; Sexton T; Kapoor A; Ward A; Zukotynski K; Emmett L; Bauman G, 2022, 'Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI', Clinical and Translational Radiation Oncology, 32, pp. 41 - 47, http://dx.doi.org/10.1016/j.ctro.2021.11.006

Dimitriou F; Lo SN; Tan AC; Emmett L; Kapoor R; Carlino MS; Long GV; Menzies AM, 2022, 'FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma', Annals of Oncology, 33, pp. 99 - 106, http://dx.doi.org/10.1016/j.annonc.2021.10.003

Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG, 2022, 'Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study', Journal of Nuclear Medicine, 63, pp. 1531 - 1536, http://dx.doi.org/10.2967/jnumed.121.263139

Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD, 2022, 'Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer', Journal of Nuclear Medicine, 63, pp. 1659 - 1664, http://dx.doi.org/10.2967/JNUMED.121.263743

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European Urology Oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P, 2021, 'The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study[Formula presented]', European Urology, 80, pp. 682 - 689, http://dx.doi.org/10.1016/j.eururo.2021.08.002

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

R Di Ciaccio P; Emmett L; Hamad N, 2021, 'Qualitative study of nuclear medicine physicians' perceptions of positron emission tomography/computed tomography in pregnant patients with cancer', Internal Medicine Journal, 51, pp. 1722 - 1726, http://dx.doi.org/10.1111/imj.15515

Dhiantravan N; Emmett L; Joshua AM; Pattison DA; Francis RJ; Williams S; Sandhu S; Davis ID; Vela I; Neha N; Bressel M; Murphy DG; Hofman MS; Azad AA, 2021, 'UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)', BJU International, 128, pp. 331 - 342, http://dx.doi.org/10.1111/bju.15384

Hofman MS; Sandhu S; Francis RJ; Davis ID; Emmett L, 2021, 'Targeted radioactive therapy for prostate cancer – Authors' reply', Lancet, 398, pp. 488, http://dx.doi.org/10.1016/S0140-6736(21)01060-6

Meijer D; van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study', European Urology, 80, pp. 234 - 242, http://dx.doi.org/10.1016/j.eururo.2021.05.006

Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL, 2021, 'Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA–D Melanoma', Annals of Surgical Oncology, 28, pp. 4561 - 4569, http://dx.doi.org/10.1245/s10434-020-09270-3

Mei R; Bracarda S; Emmett L; Farolfi A; Lambertini A; Fanti S; Castellucci P, 2021, 'Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT', Clinical and Translational Imaging, 9, pp. 215 - 220, http://dx.doi.org/10.1007/s40336-021-00421-4

Luiting HB; Remmers S; Meijer D; Vis AN; Donswijk M; Oprea-Lager DE; Emmett L; Rauscher I; Van der Poel HG; Roobol MJ; van Leeuwen PJ, 2021, 'External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?', European Urology Open Science, 28, pp. 47 - 51, http://dx.doi.org/10.1016/j.euros.2021.04.002

Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N, 2021, 'Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer', Future Oncology, 17, pp. 2225 - 2241, http://dx.doi.org/10.2217/fon-2020-1293

Long GV; Atkinson V; Lo S; Guminski AD; Sandhu SK; Brown MP; Gonzalez M; Scolyer RA; Emmett L; McArthur GA; Menzies AM, 2021, 'Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).', Journal of Clinical Oncology, 39, pp. 9508 - 9508, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9508

Ceci F; Oprea-Lager DE; Emmett L; Adam JA; Bomanji J; Czernin J; Eiber M; Haberkorn U; Hofman MS; Hope TA; Kumar R; Rowe SP; Schwarzenboeck SM; Fanti S; Herrmann K, 2021, 'E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 1626 - 1638, http://dx.doi.org/10.1007/s00259-021-05245-y

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID; Dhiantravan N; Ford K; Langford A; Lawrence N; McDonald W; Rana N; Subramaniam S; Yip S, 2021, '[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', Lancet, 397, pp. 797 - 804, http://dx.doi.org/10.1016/S0140-6736(21)00237-3

Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J, 2021, '⁶⁸Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 477 - 482, http://dx.doi.org/10.1007/s00259-020-04944-2

Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J, 2021, 'Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 655 - 656, http://dx.doi.org/10.1007/s00259-020-04983-9

Fendler WP; Calais J; Eiber M; Simko JP; Kurhanewicz J; Santos RD; Feng FY; Reiter RE; Rettig MB; Nickols NG; Kishan AU; Shozo O; Emmett L; Zacho HD; Ilhan H; Rischpler C; Wetter A; Schoder H; Burger IA; Slavik R; Carroll PR; Lawhn-Heath C; Herrmann K; Czernin J; Hope TA, 2021, 'False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 501 - 508, http://dx.doi.org/10.1007/s00259-020-04945-1

Ende J; Amin A; Sheehan-Dare G; Cusick T; Ho B; Keane J; Nguyen A; Liu V; Lee J; Chan L; Chen A; Fullard K; Stricker P; Emmett L, 2021, 'Pilot Trial Comparing the Performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/ CT in the Detection of Prostate Cancer Recurrence in Men with Rising PSA Following Radical Prostatectomy', Journal of Radiology and Medical Imaging, https://meddocsonline.org/journal-of-radiology-and-medical-imaging/pilot-trial-comparing-the-performance-of-68Ga-PSMA-11-PET-CT-to-18F-PSMA-1007-PET-CT-in-the-detection-of-prostate-cancer-recurrence-in-men-with-rising-PSA-following-radical-prostatectomy.pdf

McGeorge S; Kwok M; Jiang A; Emmett L; Pattison DA; Thomas PA; Yaxley JW; Roberts MJ, 2021, 'Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review', Advances in Urology, 2021, http://dx.doi.org/10.1155/2021/1544208

Lawhn-Heath C; Salavati A; Behr SC; Rowe SP; Calais J; Fendler WP; Eiber M; Emmett L; Hofman MS; Hope TA, 2021, 'Prostate-specific membrane antigen PET in prostate cancer', Radiology, 299, pp. 248 - 260, http://dx.doi.org/10.1148/RADIOL.2021202771

Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G, 2021, 'Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging', Advances in Radiation Oncology, 6, http://dx.doi.org/10.1016/j.adro.2020.08.010

Meijer D; Van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van De Ven PM; Van Der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External validation and addition of PSMA-PET to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: An international multicenter study', European Urology Open Science, 33, pp. S191 - S193, http://dx.doi.org/10.1016/s2666-1683(21)03073-1

De Bono J; Delaney E; Emmett L; Florisson D; Ghani M; Kemp S; Smith J, 2021, 'M13 Cardiac Surgery Advanced Life Support – A Unique Approach and Learning Program', Heart, Lung and Circulation, 30, pp. S6 - S7, http://dx.doi.org/10.1016/j.hlc.2021.03.022

Zamboglou C; Schmidt-Hegemann NS; Emmett L; Strouthos I; Ferentinos K; Serani F; Farolfi A; Fanti S; Federica M; Lanzafame H; Kirste S; Ruf J; Vrachimis A; Ceci F; Grosu AL; Henkenberens C, 2021, 'Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis', European Urology Open Science, 33, pp. S261 - S262, http://dx.doi.org/10.1016/s2666-1683(21)03122-0

Meijer D; van Leeuwen P; Roberts M; Siriwardana A; Morton A; Yaxley J; Samaratunga H; Emmett L; van de Ven P; van der Poel H; Donswijk M; Boellaard T; Schoots I; Oprea-Lager D; Coughlin G; Vis A, 2021, 'MP11-13 EXTERNAL VALIDATION AND ADDITION OF PSMA-PET TO THE MOST FREQUENTLY USED NOMOGRAMS FOR THE PREDICTION OF PELVIC LYMPH-NODE METASTASES: AN INTERNATIONAL MULTICENTER STUDY', Journal of Urology, 206, http://dx.doi.org/10.1097/ju.0000000000001984.13

Gondoputro W; Blazevski A; Amin A; Scheltema M; Agrawal S; Cusick T; Van Leeuwen P; Van Leeuwen F; Emmett L; Thompson J; Stricker P, 2021, 'MP50-05 INTERIM RESULTS FROM THE DETECT TRIAL: A PROSPECTIVE CLINICAL TRIAL EVALUATING ^99M TC-LABELLED PSMA RADIOGUIDED SURGERY TO AID THE INTRAOPERATIVE DETECTION OF LYMPH NODE METASTASES DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER', Journal of Urology, 206, http://dx.doi.org/10.1097/ju.0000000000002076.05

Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; Van Leeuwen PJ; Van Der Poel HG, 2021, 'Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT', European Urology Open Science, 33, pp. S194 - S197, http://dx.doi.org/10.1016/s2666-1683(21)03074-3

Emmett L; Hruby G, 2020, 'Clinical impact of PET imaging in prostate cancer management', Current Opinion in Urology, 30, pp. 649 - 653, http://dx.doi.org/10.1097/MOU.0000000000000795

Emmett L, 2020, 'Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer', Seminars in Oncology Nursing, 36, http://dx.doi.org/10.1016/j.soncn.2020.151052

Lee J; Emmett L; Tang R; Ho B; Earls P; Matthews T; Gallagher R, 2020, 'Prospective evaluation of the impact of human papilloma virus status and small node size on the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for primary head and neck squamous cell carcinoma', ANZ Journal of Surgery, 90, pp. 1396 - 1401, http://dx.doi.org/10.1111/ans.16093

Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P, 2020, '3-year freedom from progression after 68Ga-PSMA PET/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial', Journal of Nuclear Medicine, 61, pp. 866 - 872, http://dx.doi.org/10.2967/jnumed.119.235028

Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ, 2020, 'Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (68Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection', BJU International, 125, pp. 876 - 883, http://dx.doi.org/10.1111/bju.15052

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', Journal of Clinical Oncology, 38, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5500

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L, 2020, 'Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer', BJU International, 125, pp. 515 - 524, http://dx.doi.org/10.1111/bju.14999

Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G, 2020, 'A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy', International Journal of Radiation Oncology Biology Physics, 106, pp. 546 - 555, http://dx.doi.org/10.1016/j.ijrobp.2019.11.001

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ, 2020, 'Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature', BJU International, 125, pp. 206 - 214, http://dx.doi.org/10.1111/bju.14944

Emmett L; Hofman MS, 2020, 'Editorial Comment', Journal of Urology, 203, pp. 99, http://dx.doi.org/10.1097/01.JU.0000605568.03568.2c

Holtkamp LHJ; Chakera AH; Fung S; Stretch JR; Saw RPM; Lee K; Ch'Ng S; Gonzalez M; Thompson JF; Emmett L; Nieweg OE, 2020, 'Staging ¹⁸F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases', Melanoma Research, pp. 358 - 363, http://dx.doi.org/10.1097/CMR.0000000000000666

Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L, 2019, 'Diagnostic accuracy of 68Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68Ga-PSMA PET to mpMRI', BJU International, 124, pp. 42 - 49, http://dx.doi.org/10.1111/bju.14794

Back to profile page